Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DE09IO
|
|||
| Drug Name |
BNZ-1
|
|||
| Drug Type |
Peptide
|
|||
| Indication | Cutaneous T-cell lymphoma [ICD-11: 2B01; ICD-10: C84.8; ICD-9: 202.1, 202.2] | Phase 2 | [1] | |
| T-cell leukaemia [ICD-11: 2A90; ICD-10: C86] | Phase 2 | [2] | ||
| Large granular lymphocytic leukemia [ICD-11: 2A90.1] | Phase 1/2 | [3] | ||
| Company |
Bioniz Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT03239392) A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL. U.S. National Institutes of Health. | |||
| REF 4 | Clinical pipeline report, company report or official report of Bioniz Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.